VIVUS (VVUS) Tops Q2 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
VIVUS Reports 2016 Second Quarter Financial Results
August 4, 2016 4:16 PM EDTMOUNTAIN VIEW, CA -- (Marketwired) -- 08/04/16 -- VIVUS, Inc. (NASDAQ: VVUS) (The "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the second quarter ended June 30, 2016. The net loss for the 2016 second quarter was $11.4 million as compared to $49.4 million in 2015. Cash, cash equivalents and available-for-sale securities was $220.2 million at June 30, 2016.
"In the second quarter of 2016, we made significant strides to optimize the value of Qsymia and STENDRA," said Seth H. Z. Fischer,... More
